Sponsor

Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)

Spain Dr. Esquerdo, 105, 28007 Madrid, Spain

About the sponsor

Research activity is centered on oligometastatic castration-resistant prostate cancer, with a focus on combining stereotactic body radiotherapy with second-generation antiandrogen treatment in patients with advanced disease.

Fractionated stereotactic radiotherapy
Castration-resistant prostate cancer
Oligometastatic disease

Imaging-based assessment is linked to choline PET/CT and 68Ga-PSMA PET/CT for monitoring radiological progression in metastatic settings.

About Specializations

Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT) runs clinical trials in conditions such as Hormone-refractory prostate cancer, among others.

Hormone-refractory prostate cancer

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

1 clinical trial

Hormone-refractory prostate cancer

Recruiting

Registered drugNo placebo

Study on Radiotherapy and Antiandrogens for Patients with Advanced Prostate Cancer Using Abiraterone Acetate and Enzalutamide

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abiraterone Acetate
Sponsor:Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →